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Agent	 Company	 Type	 Clinical	trials	CA4P	(fosbretabulin,	Zybrestat)	 Oxigene	 Microtubule	destabilizing	agent	 Phase	III:	advanced	anaplastic	thyroid	cancer	(failed	to	
achieve	primary	endpoints),	ovarian	cancer	(ongoing)	Phase	II:	fallopian	tube	cancer,	peritoneal	cavity	cancer,	pancreatic	cancer,	neuroendocrine	tumours	(all	
ongoing)	Oxi4503	 Oxigene	 Microtubule	destabilizing	agent	 Phase	II:	acute	myeloid	leukaemia	(ongoing)		Phase	I:	liver	and	other	solid	tumours	(Completed	with	
positive	data)	AVE8062	(Ombrabulin)	 Sanofi-Aventis	 Microtubule	destabilizing	agent	 Phase	III:	soft	tissue	sarcoma	Phase	II:	metastatic	non-small	cell	lung	cancer,	recurrent	ovarian	cancer	(all	failed	to	
achieve	primary	endpoints)	
Discontinued	Dolastatin-10		 National	Cancer	Institute	 Microtubule	destabilizing	agent	 Phase	II:	lymphoma,	macroglobulinema,	lymphocytic	leukaemia,	colorectal	adenocarcinoma,	melanoma,	soft	tissue	sarcoma,	breast,	liver,	prostate,	pancreatic,	ovarian,	renal	and	non-small	cell	lung	cancer	(outcome	data	
unavailable)	
Not	presently	in	clinical	trials	ZD6126	 AstraZeneca/	Angiogene	pharmaceuticals	 Microtubule	destabilizing	agent	 Phase	II:	metastatic	renal	cell	carcinoma	and	colorectal	carcinoma	(failed	to	achieve	
primary	endpoints)	
Not	presently	in	clinical	trials	CYT997	 Cytopia	 Microtubule	destabilizing	agent	 Phase	II:	glioblastoma		and	myeloma	(failed	to	achieve	
primary	endpoints)	
Not	presently	in	clinical	trials	NPI	2358	(Plinabulin)	 Nereus	 Microtubule	destabilizing	agent	 Phase	III:	non-small	cell	lung	cancer	(ongoing)		BNC-105	 Bionomics	 Microtubule	destabilizing	agent	 Phase	II:	renal	cell	carcinoma	(ongoing)	and	ovarian	cancer	
(terminated)	DMXAA	(Vadimezan,	ASA404)	 Novartis	 Cytokine	inducing	agent	 Phase	II:	metastatic	prostate	cancer,	non-small	cell	lung	cancer	and	urothelial	carcinoma	
(outcome	data	unavailable)	
















































































































Antibody	 Company	 Antibody	type	 Target	 Indications/	clinical	trials	Bevacizumab	(Avastin)	 Genentech	 Humanised	IgG1	 VEGF-A	 FDA	approved	for:	first	and	second	line	metastatic	colorectal	carcinoma,	first-line	advanced	non-squamous	non-small	cell	lung	cancer,	metastatic	renal	cell	cancer,	recurrent	glioblastoma	multiforme.	Phase	III:	ovarian	cancer	(ongoing)	
FDA	approval	revoked	for	metastatic	
breast	cancer	Ramucirumab	(IMC-1121b)	 ImClone	Systems	 Fully	human	IgG1	 VEGFR-2	 FDA	approved	for:	second-line	advanced	gastric	or	gastro-esophageal	junction	adenocarcinoma	and	metastatic	non-small	cell	lung	cancer.	Phase	III:	breast	cancer,	hepatocellular	carcinoma,	metastatic	colorectal	carcinoma.	Phase	II:	stomach,	renal,	bladder,	prostate,	ovarian	cancers	and	melanoma	(all	ongoing)	CDP-791	 Celltech	 Pegylated	humanised	DiFab	 VEGFR-2	 Phase	II:	non-squamous	non-small-cell	lung	cancer	(failed	to	achieve	primary	





























































trials	ongoing),	colorectal	and	lung	cancer	(ongoing)	Sorafenib	 Nexavar,	BAY	43-9006	 Bayer	HealthCare	Pharmaceuticals	and	Onyx	Pharmaceuticals	 VEGFR2	&	3,	Raf,	PDGFRβ,	Flt3	and	c-kit	
FDA	approved	for:	unresectable	hepatocellular	carcinoma,	advanced	renal	cell	carcinoma	Phase	III:	non-small	cell	lung	carcinoma	and	melanoma	(failed	to	achieve	
primary	endpoints	in	both)	Pazopanib	 Armala,	GW786034	 GlaxoSmithKline	plc	 VEGFR1-3,	PDGFRα	&	
β,	c-kit	 FDA	approved	for:	renal	cell	carcinoma,	soft	tissue	sarcoma	Phase	II:	non-small	cell	lung	carcinoma	
(failed	to	achieve	primary	
endpoints),	ovarian	cancer	(ongoing)	Phase	I:	colorectal	cancer	Axitinib	 AG-013736	Inlyta	 Pfizer	 VEGFR1-3,	PDGFRβ,	c-kit	 FDA	approved	for:	second	line	treatment	for	renal	cell	carcinoma	Phase	III:	pancreatic	cancer	(failed	to	
achieve	primary	endpoints)	Phase	II:	lung,	gastrointestinal,	thyroid	and	breast	cancer	(ongoing)	Vandetanib	 Zactima,	ZD6474	 Astrazeneca	 VEGFR1-3,	PDGFRβ,	EGFR,	RET	 FDA	approved	for:	medullary	thyroid	cancer	Phase	III:	non	small	cell	lung	carcinoma	
(ongoing)	Cediranib	 Recentin,	AZD2171	 Astrazeneca	 VEGFR1-3,	PDGFRα	&	b,	c-kit	 Phase	III:	recurrent	ovarian,	fallopian	tube,	primary	peritoneal	cancer,	glioblastoma,	colorectal	cancer	(all	
ongoing),	non	small	cell	lung	carcinoma	
(failed	to	achieve	primary	endpoints)		Vatalanib	 PTK787,	ZK222584	Caprelsa	 Novartis	 VEGFR1-3,	PDGFRα	&	b,	c-kit	 Phase	III:	Colorectal	carcinoma	(failed	to	achieve	primary	endpoints)	Phase	II:	Metastatic	neuroendocrine	tumours,	Brain	and	central	nervous	system	tumours,	sarcoma	(outcome	
data	unavailable)	Brivanib	alaninate			 BMs-582664			 Bristol-Myers	Squibb			 VEGFR1–3,	FGFR1-3			 Phase	III:	colorectal	cancer,	hepatocellular	carcinoma	(ongoing)	Phase	II:	multiple	tumour	types	
(ongoing)	Nintedanib		 Vargatef	BIBF	1120	 Boehringer	ingelheim			 VEGFR1–3,	PDGFRα	&	β,	FGFR1–3,	Flt3,	Src,	Fyn,	Lck			










































































































Chemicals	/	drugs	 Product	code	 Manufacturer	Sodium	azide	(NaN-3)	 S8032	 Sigma-Aldrich,	Gillingham,	UK	Glycine	 G8898	 Sigma-Aldrich,	Gillingham,	UK	Tetramethylethylenediamine	(TEMED)	 T9281	 Sigma-Aldrich,	Gillingham,	UK	Ammonium	persulphate	(APS)	 A3678	 Sigma-Aldrich,	Gillingham,	UK	Sodium	chloride	(NaCl)	 S9625	 Sigma-Aldrich,	Gillingham,	UK	IGEPAL	CA-630	 I8896	 Sigma-Aldrich,	Gillingham,	UK	Deoxycholic	acid	(DOC)	 D2510	 Sigma-Aldrich,	Gillingham,	UK	Sodium	dodecyl	sulfate	(SDS)	 A1112,0100	 AppliChem,	St	Louis,	USA	Bromophenol	blue	 B0126	 Sigma-Aldrich,	Gillingham,	UK	Glycerol	 G5516	 Sigma-Aldrich,	Gillingham,	UK	Tris(hydroxymethyl)aminomethane	(Tris)	 T1503	 Sigma-Aldrich,	Gillingham,	UK	Dithiothreitol	(DTT)	 43819	 Sigma-Aldrich,	Gillingham,	UK	Triton	X-100		 T8787	 Sigma-Aldrich,	Gillingham,	UK	Propidium	iodide		 P4170	 Sigma-Aldrich,	Gillingham,	UK	Actinomycin	D		 A9415	 Sigma-Aldrich,	Gillingham,	UK	Phosphate	buffered	saline	(PBS)		 P4417	 Sigma-Aldrich,	Gillingham,	UK	Qiazol	lysis	reagent		 79306	 Qiagen,	Manchester,	UK	Express	qPCR	Supermix	 A10312	 Invitrogen,	Paisley,	UK	Histoclear		 HS-200	 National	diagnostics,	Hessle,	UK	Ethanol	 20821-330	 VWR	chemicals,	East Grinstead, UK	Hydrogen	peroxide	 H1009	 Sigma-Aldrich,	Gillingham,	UK	Casein	solution		 SP-5020	 Vector	labs,	Orton,	UK	














Manufacturer	Bovine	serum	albumin	(BSA)	 421501L	 VWR	chemicals,	East Grinstead, 
UK	Milk		 92964	 Marvel,	St	Albans,	UK	RNAse	free	DNAse		 79254	 Qiagen,	Manchester,	UK	RNAse	A		 19101	 Qiagen,	Manchester,	UK	Collagenase	type	V	from	Clostridium	histolyticum	 C9263	 Sigma-Aldrich,	Gillingham,	UK	Biotyinylated	lectin	from	Ulex	europaeus		 L8262	 Sigma-Aldrich,	Gillingham,	UK	Medium	199	(M199)	 M2154	 Sigma-Aldrich,	Gillingham,	UK	High	glucose	Dulbecco's	Modified	Eagle	Medium	(DMEM)	 51435C		 Sigma-Aldrich,	Gillingham,	UK	Optimem	 31985070	 Gibco,	Paisley,	UK	L-Glutamine		 25030	 Gibco,	Paisley,	UK	Heparin	sodium	salt	from	porcine	intestinal	mucosa	 H3149	 Sigma-Aldrich,	Gillingham,	UK	Collagenase	1A	from	Clostridium	histolyticum	 C9891	 Sigma-Aldrich,	Gillingham,	UK	Gelatin	from	porcine	skin		 04055	 Sigma-Aldrich,	Gillingham,	UK	Fetal	calf	serum	(FCS)	 10270	 PAA,	Cambridge,	UK	Trypsin-EDTA	 L11-003		 PAA,	Cambridge,	UK	Recombinant	human	VEGF-165	 100-20	 Peprotech,	London,	UK	Brain	extract	(prepared	as	described	in	(191))	 N/A	 N/A		
	
Table	2.4.	Kits	used	for	the	research	detailed	in	this	thesis.	







Tissue	arrays	 Product	code	 Manufacturer	Human,	common	cancers	(1)	 MA2	 Superbiochip,	Seoul,	Korea	Human,	normal	matching	tissue	of	MA2	 MAN2	 Superbiochip,	Seoul,	Korea	Human,	common	cancers	(2)	 MB4	 Superbiochip,	Seoul,	Korea	Human,	normal	matching	tissue	of	MB4	 MBN4	 Superbiochip,	Seoul,	Korea	Human,	common	cancers	(3)	 MC4	 Superbiochip,	Seoul,	Korea	Human,	normal	matching	tissue	of	MC4	 MCN4	 Superbiochip,	Seoul,	Korea	Human,	colorectal	cancer	 CD4	 Superbiochip,	Seoul,	Korea	Human,	normal	colon	and	rectum	(matching	CD4)	 CDN4	 Superbiochip,	Seoul,	Korea	Human,	colorectal	cancer-metastasis-normal	 CDA3	 Superbiochip,	Seoul,	Korea	Human,	Kidney	cancer	 CL2	 Superbiochip,	Seoul,	Korea	Kidney	clear	cell	carcinoma	 Hkid-CRC180Sur-01	 US	biomax,	Rockville,	USA	Kidney	cancer	with	matched	normal	adjacent	tissue	and	metastatic	carcinoma	 KD951a	 US	biomax,	Rockville,	USA	Kidney	disease	spectrum	(kidney	cancer	progression)	 BC07001	 US	biomax,	Rockville,	USA	Kidney	disease	spectrum	(renal	cancer	progression)	 KD807	 US	biomax,	Rockville,	USA		
	
Table	2.6.	Other	materials	used	for	the	research	detailed	in	this	thesis.	





















Concentration	Human	MCAM	 Rabbit	polyclonal	 HPA008848	 Sigma-Aldrich,	Gillingham,	UK	 225-374aa	(Extracellular	region)	 1.500-1.1000	(IHC)	1.1000	(WB)	[0.3-0.6	μg/ml]	Human	LAMA4	 Rabbit	polyclonal	 HPA015693	 Sigma-Aldrich,	Gillingham,	UK	 638-777aa	 1.200	(IHC)	[0.5	μg/ml]	Human	PECAM	 Mouse	monoclonal	 JC70A	 Dako,	Cambridge,	UK	 Cell	membrane	preparation	from	the	spleen	of	a	patient	with	hairy	cell	leukaemia	
1.100	(IHC)	[2	μg/ml]	
Human	GRIN2D	 Vaccinated	rabbit	serum	 Custom-	7GB14072-686	 Eurogenetec,	Southampton,	UK	 1-78aa	(Extracellular	region)	 1.500	(IHC)	Mouse	PECAM	(1)	 Rabbit	polyclonal	 ab28364	 Abcam,	Cambridge,	UK	 C-terminus	 1.200	(IF)		Mouse	PECAM	(2)	 Rat	monoclonal	 553369	(clone:	MEC13.3)	 BD	Falcon,	Oxford,	UK	 129/Sv	mouse-derived	endothelioma	cell	line	tEnd.1	


















Target	name		 Primer	sequences		 Probe	number		CD11b		 Fwd:	ggcatccgcaaagtggta		 9	Rev:	ggatcttaaaggcattctttcg			CD68		 Fwd:	gtccacctcgacctgctct		 1	Rev:	cactggggcaggagaaact			EPCAM		 Fwd:	ccatgtgctggtgtgtgaa		 3	Rev:	tgtgttttagttcaatgatgatcca			PDGFRA		 Fwd:	ccacctgagtgagattgtgg		 27	Rev:	tcttcaggaagtccaggtgaa			PECAM		 Fwd:	gcaacacagtccagatagctgt		 14	Rev:	gacctcaaactgggcatcat		FLOT2		 Fwd:	gatcctcagcttcaccatcaa		 61	Rev:	tcagcatctctctgcaccac		MCAM		 Fwd:	gggtaccccattcctcaagt		 63	Rev:	cagtctgggacgactgaatg		LAMA4		 Fwd:	gaccctgaggacacagtgtttta		 22	Rev:	aggcaggtttaagctggtagg		STRA6	 Fwd:	ctctggcctgactgtgtgc		 23	Rev:	tgtccccagccaagaaatc		GRIN2D		 Fwd:	ggctcagtgaccgcaagt	 57	Rev:	gcacggtcccaaacttca	FNDC1		 Fwd:	agactgaggggaaagtgaaaga		 80	Rev:	atccaccagggcagaagtag		GPR4		 Fwd:	ttccgccatccctctacat		 44	Rev:	ccacagagccaggcagtt		RGS5		 Fwd:	cccactcatgcctggaaa		 65	Rev:	tgacaaggtcaccaactgagtc		TGM2		 Fwd:	agggtgacaagagcgagatg		 86	Rev:	tggtcatccacgactccac		KCNJ8		 Fwd:	cgctacccggagtctgag	 34	Rev:	cagcttagccacctccctct	OR51E1		 Fwd:	cagcctgccagacctctt	 69	Rev:	cagcaccaggcaggtagag	
	 48	
Table	2.13.	Mouse	RTqPCR	primers	used	for	the	research	detailed	in	this	thesis.	






































































































































































































































































































































































































































































































































































































































































































































































































































































Table	4.1.	Known	tumour	associated	or	angiogenic	genes	enriched	in	colorectal	cancer	vessels.		Gene	ID	 Gene	Symbol	 GeneBank	accession	no.	 LogFC	P-value	Interleukin	8	 IL8	 NM_000584	 3.42	 0.00	Angiopoietin	2	 ANGPT2	 NM_001147	 3.40	 0.00	Plexin	domain	containing	1	 PLXDC1	 NM_020405	 3.12	 0.01	Lysyl	oxidase-like	2	 LOXL2	 NM_002318	 3.11	 0.01	Hairy/enhancer-of-split	related	with	YRPW	motif-like	 HEYL	 NM_014571	 3.01	 0.00	Placental	growth	factor	 PGF	 NM_002632	 2.92	 0.01	Platelet-derived	growth	factor	receptor,	beta	polypeptide	 PDGFRB	 NM_002609	 2.82	 0.00	Endothelial	cell-specific	molecule	1	 ESM1	 NM_007036	 2.63	 0.00	CD86	molecule	 CD86	 NM_006889	 2.42	 0.05	Apelin	 APLN	 NM_017413	 1.98	 0.00	Insulin-like	growth	factor	binding	protein	7	 IGFBP7	 NM_001553	 1.93	 0.01	Angiopoietin-like	2	 ANGPTL2	 NM_012098	 1.65	 0.09	Major	histocompatibility	complex,	class	II,	DR	alpha	 HLA-DRA	 NM_019111	 1.65	 0.05	Tenascin	C	 TNC	 NM_002160	 1.42	 0.12	Secreted	protein,	acidic,	cysteine-rich	(osteonectin)	 SPARC	 NM_003118	 1.39	 0.13	Neuropilin	1	 NRP1	 NM_001024629	 1.23	 0.08	Lysyl	oxidase	 LOX	 NM_002317	 1.20	 0.21	Anthrax	toxin	receptor	1	 ANTXR1	 NM_053034	 1.01	 0.20		
Table	4.2.	Collagens	enriched	in	colorectal	cancer	vessels.	
 
Gene	ID	 Gene	Symbol	 GeneBank	accession	no.	 LogFC	 P-value	
Collagen,	type	I,	alpha	1	 COL1A1	 NM_000088	 4.18	 0.00	
Collagen,	type	XII,	alpha	1	 COL12A1	 NM_004370	 3.13	 0.00	
Collagen,	type	IV,	alpha	1	 COL4A1	 NM_001845	 2.86	 0.00	
Collagen,	type	I,	alpha	2	 COL1A2	 NM_000089	 2.79	 0.01	
Collagen,	type	XV,	alpha	1	 COL15A1	 NM_001855	 2.56	 0.01	
Collagen,	type	XVIII,	alpha	1	 COL18A1	 NM_030582	 2.42	 0.00	
Collagen,	type	IV,	alpha	2	 COL4A2	 NM_001846	 2.36	 0.00	
Collagen,	type	V,	alpha	1	 COL5A1	 NM_000093	 2.30	 0.04	
Collagen,	type	VIII,	alpha	1	 COL8A1	 NM_001850	 2.28	 0.02	
Collagen,	type	V,	alpha	2	 COL5A2	 NM_000393	 2.10	 0.03	
Collagen,	type	VII,	alpha	1	 COL7A1	 NM_000094	 2.00	 0.17	
Collagen,	type	V,	alpha	3	 COL5A3	 NM_015719	 1.79	 0.01	
Collagen,	type	X,	alpha	1	 COL10A1	 NM_000493	 1.69	 0.06	
Collagen,	type	III,	alpha	1	 COL3A1	 NM_000090	 1.66	 0.10	
Collagen,	type	XIV,	alpha	1	 COL14A1	 NM_021110	 1.54	 0.08	
Collagen,	type	VI,	alpha	1	 COL6A1	 NM_001848	 1.45	 0.14	
Collagen,	type	VI,	alpha	3	 COL6A3	 NM_004369	 1.44	 0.08	






Gene	ID	 Gene	Symbol	 GeneBank	accession	no.	 LogFC	 P-value	
Matrix	metallopeptidase	3	(stromelysin	1,	progelatinase)	 MMP3	 NM_002422	 5.72	 0.01	
Matrix	metallopeptidase	7	(matrilysin,	uterine)	 MMP7	 NM_002423	 5.54	 0.00	
Matrix	metallopeptidase	12	(macrophage	elastase)	 MMP12	 NM_002426	 4.86	 0.00	
Matrix	metallopeptidase	1	(interstitial	collagenase)	 MMP1	 NM_002421	 4.49	 0.04	
Matrix	metallopeptidase	9	(gelatinase	B)	 MMP9	 NM_004994	 4.10	 0.00	
Matrix	metallopeptidase	11	(stromelysin	3)	 MMP11	 NM_005940	 3.25	 0.01	
Matrix	metallopeptidase	10	(stromelysin	2)	 MMP10	 NM_002425	 2.54	 0.10	
Matrix	metallopeptidase	14	(membrane-inserted)	 MMP14	 NM_004995	 1.94	 0.04	
Matrix	metallopeptidase	2	(gelatinase	A)	 MMP2	 NM_004530	 1.51	 0.16	






















































































































STRA6! 30.7! 5.1! 10.6! !
GRIN2D! 35.4! 15.8! 35.0! GRIN2D!
FNDC1! 20.5! 2.4! 16.9! !
GPR4! 22.7! 8.8! 17.3! !
RGS5! 3.7! 1.0! 109.1! !
TGM2! 1.7! 0.5! 841.7! !
KCNJ8! 7.5! 6.25! 4.4! !



























































































































































































































































































































































































































































Collagen,	type	I,	alpha	1 COL1A1 NM_000088 1.47 4.18 3.88 3.17 
Collagen,	type	I,	alpha	2 COL1A2 NM_000089 1.18 2.79 2.36 2.20 
Collagen,	type	III,	alpha	1 COL3A1 NM_000090 0.62 1.66 1.64 1.41 
Collagen,	type	IV,	alpha	1 COL4A1 NM_001845 1.85 2.86 3.13 1.70 
Collagen,	type	IV,	alpha	2 COL4A2 NM_001846 1.19 2.36 2.08 1.31 
Collagen,	type	IV,	alpha	3 COL4A3 NM_000091 -1.29 -0.36 -0.09 -0.63 
Collagen,	type	IV,	alpha	4 COL4A4 NM_000092 -1.29 -0.97 0.39 -1.48 
Collagen,	type	IV,	alpha	5 COL4A5 NM_033380 -1.32 -1.20 -2.67 -1.73 
Collagen,	type	V,	alpha	1 COL5A1 NM_000093 1.02 2.30 2.23 2.09 
Collagen,	type	V,	alpha	2 COL5A2 NM_000393 1.24 2.10 1.80 2.25 
Collagen,	type	V,	alpha	3 COL5A3 NM_015719 1.29 1.79 0.23 -0.19 
Collagen,	type	VI,	alpha	1 COL6A1 NM_001848 0.75 1.45 -0.27 -0.08 
Collagen,	type	VI,	alpha	2 COL6A2 NM_058175 1.71 0.23 0.97 0.25 
Collagen,	type	VI,	alpha	3 COL6A3 NM_004369 0.52 1.44 1.22 1.72 
Collagen,	type	VI,	alpha	6 COL6A6 NM_001102608 -0.42 0.07 -0.01 -1.93 
Collagen,	type	VII,	alpha	1 COL7A1 NM_000094 -1.39 2.00 1.22 1.15 
Collagen,	type	VIII,	alpha	1 COL8A1 NM_001850 2.09 2.28 2.94 1.31 
Collagen,	type	VIII,	alpha	2 COL8A2 NM_005202 0.73 0.93 0.56 1.26 
Collagen,	type	IX,	alpha	1 COL9A1 NM_001851 0.11 1.08 0.24 0.40 
Collagen,	type	IX,	alpha	3 COL9A3 NM_001853 0.29 -0.19 1.07 1.70 
Collagen,	type	X,	alpha	1 COL10A1 NM_000493 -0.05 1.69 3.03 2.40 
Collagen,	type	XII,	alpha	1 COL12A1 NM_004370 0.75 3.13 1.53 1.03 
Collagen,	type	XIV,	alpha	1 COL14A1 NM_021110 0.34 1.54 0.75 -0.09 
Collagen,	type	XV,	alpha	1 COL15A1 NM_001855 1.18 2.56 1.73 1.23 
Collagen,	type	XVI,	alpha	1 COL16A1 NM_001856 0.50 0.48 0.55 1.11 
Collagen,	type	XVII,	alpha	1 COL17A1 NM_000494 -0.37 -0.39 -0.81 2.49 
Collagen,	type	XVIII,	alpha	1 COL18A1 NM_030582 0.65 2.42 2.01 1.08 
Collagen,	type	XXI,	alpha	1 COL21A1 NM_030820 2.39 -0.84 -0.36 -1.29 
Collagen,	type	XXII,	alpha	1 COL22A1 NM_152888 -0.39 0.47 0.40 1.01 
Collagen,	type	XXIII,	alpha	1 COL23A1 NM_173465 1.53 0.10 0.15 0.08 													
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Table	5.5.	Key	clinical	data	for	different	types	of	kidney	cancer	and	metastasis.	Characteristics Clear	cell Transitional	cell Papillary	cell Squamous	cell	 Sarcomatodes 
Tumours 64 15 8 7 6 Gender 	 	 	 	 	 Male 50 13 7 5 2 Female 14 2 1 2 4 Age 	 	 	 	 	 Above	60 29 11 0 2 2 Below	60 35 4 8 5 4 T-stage 	 	 	 	 	 No	information 30 0 0 0 1 T1 23 14 8 4 0 T2 8 1 0 2 4 T3 3 0 0 1 1 M-stage 	 	 	 	 	 M0 56 15 7 7 5 M1 8 0 1 0 1 MCAM	staining 	 	 	 	 	 Strong 39 7 1 1 2 Weak 25 8 7 6 4 
%	strong	staining 60.94 46.67 12.50 14.29 33.33 
	 	 	 	 	 	 
Metastasis 15 2 2 2 1 Gender 	 	 	 	 	 Male 13 0 2 2 1 Female 2 2 0 0 0 Age 	 	 	 	 	 Above	60 11 2 0 2 1 Below	60 4 0 2 0 0 Location 	 	 	 0 	 Adrenal	gland 3 0 0 0 0 Bone 1 0 0 0 0 Lymph	node 4 2 2 2 0 Lung 3 0 0 0 0 Thyroid 1 0 0 0 0 Intestine 1 0 0 0 0 Spleen 0 0 0 0 1 Retroperitoneum 2 0 0 0 0 MCAM	staining 	 	 	 	 	 Strong 11 0 2 1 0 Weak 4 2 0 1 1 

























































































































































































































































































































Table&5.6.!Key!clinical!data!for!clear!cell!RCC!cohort!1,!showing!overall!survival!(OS).!Characteristics N!of!patients Median!OS Mean!OS All 81 69.5 63.7 Gender ! ! ! Male 48 71 65.2 Female 33 68 61.6 Age ! ! ! Above!/=60 41 69 65.1 Below!60 40 70 62.3 Grade ! ! ! G1 30 72 64.3 G1R2 10 66 59.4 G2 26 71 64.2 G2R3 4 68 61.8 G3/4 11 70 67.5 Stage ! ! ! No!information 4 R R I 55 69.5 66.1 II 16 71 59.3 III 4 63.5 58.0 IV 2 69.5 69.5 TRstage ! ! ! No!information! 2 R R T1a 34 70 66.2 T1b 24 69 61.9 T2a 13 70 57.8 T2b 3 76 76.0 T3 5 68 62.0 MRstage ! ! ! M0 79 69.5 63.5 M1 2 69.5 69.5 MCAM!staining! ! ! ! Strong 34 71 67.2 Weak 47 69 61.4 LAMA4!staining ! ! ! Strong 30 72 66.0 Weak 51 69 61.8 MCAM!and!LAMA4!coRstaining ! ! ! Both!strong 16 69 62.3 Both!weak 33 68 56.5 MCAM!strong!LAMA4!weak 18 73.5 73.5 MCAM!weak!LAMA4!strong 14 74 69.7 !!!!!
! 137!
Table&5.7.!Key!clinical!data!for!clear!cell!RCC!cohort!2,!showing!overall!survival!(OS).!Characteristics N!of!patients Median!OS Mean!OS All 48 104 86.9 Gender ! ! ! Male 35 104 81.5 Female 13 110 101.5 Age ! ! ! Above!58 26 103.5 80.9 Below!58 22 104.5 94.04 TQstage ! ! ! T1a 9 108 97.3 T1b 12 102 86.8 T2a 7 105 96 T2b 3 115 83 T3a 15 97 80.8 T3b 1 101 101 T4 1 22 22 MQstage ! ! ! M0 45 104 86.7 M1 3 110 90.3 MCAM!staining ! ! ! High 21 97 77.6 Low 27 105 94.2 LAMA4!staining ! ! ! High 17 90 71.7 Low 31 105 96.1 MCAM!and!LAMA4!coQstaining ! ! ! MCAM!and!LAMA4!strong 11 65 64.7 MCAM!and!LAMA4!weak 21 105 98.1 MCAM!strong!LAMA4!weak 10 103.5 91.8 MCAM!weak!LAMA4!strong  6 107.5 80.3 !!!!!!!!!
! 138!
Table&5.8.!Key!clinical!data!for!clear!cell!RCC!cohort!3,!showing!overall!survival!(OS).!Characteristics! N!of!patients! Median!OS! Mean!OS!All! 47! 41.50! 48.02!Gender! !! !! !!Male! 37! 43.67! 53.18!Female! 10! 24.48! 28.97!Age! !! !! !!Above!60! 27! 67.82! 68.30!Below!60! 20! 56.37! 53.41!TQstage! !! !! !!No!information! 7! !! !!T1! 6! 61.83! 58.51!T2! 1! 127.47! 127.47!T3! 31! 29.60! 37.66!T4! 2! 32.77! 32.77!MQstage! !! !! !!M0! 0! !! !!M1! 16! 48.37! 59.37!M2! 18! 29.37! 39.24!M3! 13! 29.90! 41.51!MCAM!staining! !! !! !!High! 37! 33.87! 42.96!Low! 10! 59.68! 66.76!LAMA4!staining! !! !! !!High! 34! 38.32! 44.09!Low! 13! 49.97! 58.31!MCAM!and!LAMA4!coQstaining! !! !! !!MCAM!and!LAMA4!strong! 29! 29.90! 36.04!MCAM!and!LAMA4!weak! 5! 31.57! 42.71!MCAM!strong,!LAMA4!weak! 8! 80.95! 68.05!MCAM!weak,!LAMA4!strong! 5! 88.20! 90.81!!!!!!!!!!
	 143	
















M	and	L	co-expression	(high	vs.	low)	 4.102	 1.690-9.954	 0.002	 		 		
MCAM	(high	vs.	low)	 3.402	 1.419-8.157	 		 0.006	 		
LAMA4	(high	vs.	low)	 3.297	 1.379-7.884	 		 		 0.007	
Sex	(female	vs.	male)	 0.624	 0.270-1.442	 0.27	 0.164	 0.835	
Age	(over	60	vs.	under	60)	 1.811	 0.780-3.862	 0.076	 0.058	 0.246	
Grade	(G2	and	above	vs.	G1)	 2.233	 0.881-5.660	 0.091	 0.319	 0.223	




























MCAM$T1$(n=85)$ MCAM$T2$(n=27)$ MCAM$T3$(n=52)$ MCAM$T4$(n=3)$














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Day	9	 5	 5	 10	
600	mm3	 4	 6	 10	
1300	mm3	 13	 7	 18	
***	 *	 ***	 NS	
***	 NS	






expression	of	the	six	genes	of	interest	in	end t li l	i l t s	fro 	untreated,	
responsive	and	non-responsive	tu ste 	at	9	days,	60 	mm3	and	1300	
mm3.	(mean	expression ±SEM,	***	p<0.001,	*	p<0.05,	NS	–	Not	Signiﬁcant,	Mann-
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